The U.S. FDA approved Takeda Pharmaceutical Co. Ltd.’s Fruzaqla (fruquintinib) nearly 20 days ahead of its Nov. 30 PDUFA date for adults with previously treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback